Lawyers Dicle Doğan

Dicle Doğan

Dicle Doğan

Gün + Partners

Dicle Doğan is a managing associate in Gün + Partners and she has been working for the firm since 2011.

Dicle has been specialized on life sciences, data protection and privacy and intellectual property with a special focus on trademarks and designs.

She advises corporate clients from life sciences sector, especially multinational pharmaceutical and medical device companies and industry associations. She advises and represents her clients on a wide range of issues including promotional activities, advertisement, labelling requirements, clinical trials, marketing authorization procedures, pricing and reimbursement regulations, and also assists clients in their day-to-day business activities. She is also experienced in cases of cancellation of administrative acts, including Regulations and Communiqués, issued by public institutions.

Dicle also advises corporate healthcare companies on the protection of personal data and privacy issues.

In the field of intellectual property, especially on trademarks and designs, in addition to counselling clients regarding their IP strategies and providing legal opinions, she has been involved in many litigation processes, where she represents the clients before the Courts in cancellation, invalidation, infringement, unfair competition actions and other types of actions. At the same time, she supervises and drafts oppositions and appeals on trademark and design applications before the Turkish Patent and Trademark Office.


Practice Areas & Work Department

Life Sciences

Intellectual Property

Trademarks and Designs

Data Protection and Privacy


Languages

English

Turkish

French

German

Update on the Medical Devices Regulations in Turkey

The main framework for ensuring safety and compliance with the technical specifications is governed by the Law on Product Safety and Technical Specifications No. 7,223, which is an umbrella legislation covering all products intended to be placed on the market, supplied, or placed on the Turkish market.

12.09.2024

Guideline on Circumstances Requiring Reissue of a Marketing Authorization For a Licensed Pharmaceutical

The transfer of pharmaceutical marketing authorizations entails intricate and interconnected procedures.

03.09.2024

Food Supplements

With the regulations published in the Official Gazette numbered 32169 and dated April 20, 2023, comprehensive amendments were made to the legislation on the use of health claims for food and food supplements and the use of nutrition claims.

27.08.2024

Interactions with HCPs, Transfer of Values and Payments

The Regulation on the Promotional Activities of Pharmaceutical Products for Human Use, dated July 3, 2015, regulates the promotional activities of medicinal products for human use.

22.08.2024

Named Patient Program

Named Patient Programs is one of the exceptional pharmaceutical importation regimes for products that are not authorized or authorized but unavailable in the Turkish market for various reasons.

19.08.2024

Market Access – Alternative Reimbursement Models

In the presence of alternative reimbursement models such as payback, value-based, indication-based reimbursement, performance-based, etc., developed for drug reimbursement systems throughout the world, ...

15.08.2024

Pricing of Pharmaceuticals and the Fixed Exchange Rate

Due to the rapid increase in the current exchange rates, pharmaceutical prices have been one of the most controversial issues in Türkiye in 2023.

14.08.2024

Guidelines on Packaging Information and Instructions for Use of Pharmaceuticals have been Updated

On June 11, 2024, the Turkish Medicines and Medical Devices Agency announced on its official website that the “Guideline on the Packaging Information and Instructions for Use of Medicinal Products for Human Use”, “Guideline on the Readability of the Packaging Information and Instructions for Use of Medicinal Products for Human Use” and “Guideline on Excipients in the Packaging Information and Instructions for Use of Medicinal Products for Human Use” have all been amended.

16.07.2024
Load More
Ready to stay ahead of the curve?
Share your interest anonymously and let us guide you through the informative articles on the hottest legal topics.
|
Successful Your message has been sent